• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重组溶酶体α-葡萄糖苷酶(rhGAA)体外将糖原中的可溶性糖基化蛋白释放及其在体内血清中的存在。

The Release of a Soluble Glycosylated Protein from Glycogen by Recombinant Lysosomal α-Glucosidase (rhGAA) In Vitro and Its Presence in Serum In Vivo.

机构信息

HIBM Research Group, Inc., Glycan Technologies, Inc., P.O. Box 17993, Irvine, CA 92623, USA.

出版信息

Biomolecules. 2020 Nov 29;10(12):1613. doi: 10.3390/biom10121613.

DOI:10.3390/biom10121613
PMID:33260301
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7761001/
Abstract

In studies on the degradation of glycogen by rhGAA, a glycosylated protein core material was found which consists of about 5-6% of the total starting glycogen. There was an additional 25% of the glycogen unaccounted for based on glucose released. After incubation of glycogen with rhGAA until no more glucose was released, no other carbohydrate was detected on HPAEC-PAD. Several oligosaccharides are then detectable if the medium is first boiled in 0.1 N HCl or incubated with trypsin. It is present in serum either in an HCl extract or in a trypsin digest. The characteristics of the in vivo serum material are identical to the material in the in vitro incubation medium. One oligosaccharide cannot be further degraded by rhGAA, from the incubation medium as well as from serum co-elute on HPAEC-PAD. Several masked oligosaccharides in serum contain -inositol, -inositol, and sorbitol as the major carbohydrates. The presence of this glycosylated protein in serum is a fraction of glycogen that is degraded outside the lysosome and the cell. The glycosylated protein in the serum is not present in the serum of Pompe mice not on ERT, but it is present in the serum of Pompe disease patients who are on ERT, so it is a biomarker of GAA degradation of lysosomal glycogen.

摘要

在 rhGAA 降解糖原的研究中,发现了一种糖基化蛋白核心物质,它约占起始糖原总量的 5-6%。根据释放的葡萄糖计算,还有 25%的糖原无法解释。在用 rhGAA 孵育糖原直到不再释放葡萄糖后,如果先将培养基在 0.1N HCl 中煮沸或用胰蛋白酶孵育,就可以检测到其他 25%的碳水化合物。如果先将培养基在 0.1N HCl 中煮沸或用胰蛋白酶孵育,就可以检测到几种低聚糖。在血清中,无论是 HCl 提取物还是胰蛋白酶消化物中,都存在这种物质。体内血清物质的特征与体外孵育培养基中的物质相同。一种低聚糖不能被 rhGAA 进一步降解,无论是在孵育培养基中还是在血清中,都可以通过 HPAEC-PAD 洗脱出来。血清中的几种掩蔽低聚糖含有肌醇、肌醇和山梨醇等主要碳水化合物。这种糖基化蛋白存在于血清中,是溶酶体和细胞外降解的糖原的一部分。在未接受 ERT 的庞贝病小鼠的血清中不存在这种糖基化蛋白,但在接受 ERT 的庞贝病患者的血清中存在,因此它是溶酶体糖原 GAA 降解的生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b09/7761001/68596cb93256/biomolecules-10-01613-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b09/7761001/d4b0af22d6ad/biomolecules-10-01613-g001a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b09/7761001/e28cfb57ae83/biomolecules-10-01613-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b09/7761001/80e6246e0c91/biomolecules-10-01613-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b09/7761001/d56865037ed2/biomolecules-10-01613-g004a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b09/7761001/ecbb36aecb65/biomolecules-10-01613-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b09/7761001/8da75b98c6a1/biomolecules-10-01613-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b09/7761001/a64156d54567/biomolecules-10-01613-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b09/7761001/300782f761c3/biomolecules-10-01613-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b09/7761001/d6c9dce808f7/biomolecules-10-01613-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b09/7761001/c08d4595163f/biomolecules-10-01613-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b09/7761001/68596cb93256/biomolecules-10-01613-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b09/7761001/d4b0af22d6ad/biomolecules-10-01613-g001a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b09/7761001/e28cfb57ae83/biomolecules-10-01613-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b09/7761001/80e6246e0c91/biomolecules-10-01613-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b09/7761001/d56865037ed2/biomolecules-10-01613-g004a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b09/7761001/ecbb36aecb65/biomolecules-10-01613-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b09/7761001/8da75b98c6a1/biomolecules-10-01613-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b09/7761001/a64156d54567/biomolecules-10-01613-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b09/7761001/300782f761c3/biomolecules-10-01613-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b09/7761001/d6c9dce808f7/biomolecules-10-01613-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b09/7761001/c08d4595163f/biomolecules-10-01613-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b09/7761001/68596cb93256/biomolecules-10-01613-g011.jpg

相似文献

1
The Release of a Soluble Glycosylated Protein from Glycogen by Recombinant Lysosomal α-Glucosidase (rhGAA) In Vitro and Its Presence in Serum In Vivo.重组溶酶体α-葡萄糖苷酶(rhGAA)体外将糖原中的可溶性糖基化蛋白释放及其在体内血清中的存在。
Biomolecules. 2020 Nov 29;10(12):1613. doi: 10.3390/biom10121613.
2
Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.针对庞贝病中溶酶体和细胞质糖原的抗体介导酶替代疗法。
J Mol Med (Berl). 2017 May;95(5):513-521. doi: 10.1007/s00109-017-1505-9. Epub 2017 Feb 2.
3
The pharmacological chaperone AT2220 increases recombinant human acid α-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease.药理学伴侣 AT2220 可增加重组人酸性 α-葡萄糖苷酶在 Pompe 病小鼠模型中的摄取和糖原减少。
PLoS One. 2012;7(7):e40776. doi: 10.1371/journal.pone.0040776. Epub 2012 Jul 18.
4
Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease.对用于治疗庞贝病的不同重组酸性α-葡萄糖苷酶制剂的生化和药理学特性进行评估。
Mol Genet Metab. 2008 Aug;94(4):448-455. doi: 10.1016/j.ymgme.2008.04.009. Epub 2008 Jun 5.
5
Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice.对不依赖阳离子的甘露糖6-磷酸受体具有更高亲和力的碳水化合物重塑酸性α-葡萄糖苷酶在庞贝氏症小鼠的肌肉中表现出更好的递送效果。
Biochem J. 2005 Aug 1;389(Pt 3):619-28. doi: 10.1042/BJ20050364.
6
Conjugation of mannose 6-phosphate-containing oligosaccharides to acid alpha-glucosidase improves the clearance of glycogen in pompe mice.含6-磷酸甘露糖的寡糖与酸性α-葡萄糖苷酶的缀合改善了庞贝氏症小鼠糖原的清除率。
J Biol Chem. 2004 Nov 26;279(48):50336-41. doi: 10.1074/jbc.M409676200. Epub 2004 Sep 21.
7
Endolysosomal N-glycan processing is critical to attain the most active form of the enzyme acid alpha-glucosidase.内体溶酶体 N-聚糖加工对于获得酶酸性α-葡萄糖苷酶的最活跃形式至关重要。
J Biol Chem. 2021 Jan-Jun;296:100769. doi: 10.1016/j.jbc.2021.100769. Epub 2021 May 8.
8
Reveglucosidase alfa (BMN 701), an IGF2-Tagged rhAcid α-Glucosidase, Improves Respiratory Functional Parameters in a Murine Model of Pompe Disease.瑞维葡糖苷酶α(BMN 701),一种IGF2标记的重组酸性α-葡萄糖苷酶,可改善庞贝病小鼠模型的呼吸功能参数。
J Pharmacol Exp Ther. 2017 Feb;360(2):313-323. doi: 10.1124/jpet.116.235952. Epub 2016 Nov 16.
9
Efficient therapy for refractory Pompe disease by mannose 6-phosphate analogue grafting on acid α-glucosidase.甘露糖-6-磷酸类似物接枝酸性α-葡萄糖苷酶治疗难治性庞贝病的高效疗法。
J Control Release. 2018 Jan 10;269:15-23. doi: 10.1016/j.jconrel.2017.10.043. Epub 2017 Nov 3.
10
Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.替代庞贝病中的酸性α-葡萄糖苷酶:重组酶和转基因酶效力相当,但均不能完全清除II型肌纤维中的糖原。
Mol Ther. 2005 Jan;11(1):48-56. doi: 10.1016/j.ymthe.2004.09.017.

引用本文的文献

1
Combined targeted and untargeted high-resolution mass spectrometry analyses to investigate metabolic alterations in pompe disease.联合靶向和非靶向高分辨率质谱分析研究庞贝病的代谢改变。
Metabolomics. 2023 Mar 29;19(4):29. doi: 10.1007/s11306-023-01989-w.
2
Lysosomal Storage Disorders: Molecular Basis and Therapeutic Approaches.溶酶体贮积症:分子基础与治疗方法。
Biomolecules. 2021 Jun 30;11(7):964. doi: 10.3390/biom11070964.

本文引用的文献

1
Variable clinical features and genotype-phenotype correlations in 18 patients with late-onset Pompe disease.18例晚发型庞贝病患者的临床特征及基因型-表型相关性
Ann Transl Med. 2019 Jul;7(13):276. doi: 10.21037/atm.2019.06.48.
2
Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.接受阿糖苷酶α治疗的晚发型庞贝病患者的前瞻性探索性肌肉活检、影像学及功能评估:EMBASSY研究
Mol Genet Metab. 2016 Sep;119(1-2):115-23. doi: 10.1016/j.ymgme.2016.05.013. Epub 2016 May 19.
3
Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease.
转录因子 EB(TFEB)是庞贝病的一个新的治疗靶点。
EMBO Mol Med. 2013 May;5(5):691-706. doi: 10.1002/emmm.201202176. Epub 2013 Apr 18.
4
WITHDRAWN: Clearance of lysosomal glycogen accumulation by Transcription factor EB (TFEB) in muscle cells from lysosomal alpha-glucosidase deficient mice.撤回:转录因子EB(TFEB)清除溶酶体α-葡萄糖苷酶缺陷小鼠肌肉细胞中溶酶体糖原积累的研究
Biochem Biophys Res Commun. 2013 Feb 14. doi: 10.1016/j.bbrc.2013.02.026.
5
Glycogen and its metabolism: some new developments and old themes.糖原及其代谢:一些新进展和旧主题。
Biochem J. 2012 Feb 1;441(3):763-87. doi: 10.1042/BJ20111416.
6
Transcriptional activation of lysosomal exocytosis promotes cellular clearance.转录激活溶酶体胞吐作用促进细胞清除。
Dev Cell. 2011 Sep 13;21(3):421-30. doi: 10.1016/j.devcel.2011.07.016. Epub 2011 Sep 1.
7
Long-term follow-up results in enzyme replacement therapy for Pompe disease: a case report.庞贝病酶替代疗法的长期随访结果:一例报告。
J Inherit Metab Dis. 2010 Dec;33 Suppl 3:S389-93. doi: 10.1007/s10545-010-9195-2. Epub 2010 Sep 10.
8
Observations on the chemistry of liver glycogen.关于肝糖原化学的观察
Biochem J. 1934;28(3):882-9. doi: 10.1042/bj0280882.
9
Ethephon-Induced Gummosis in Sour Cherry (Prunus cerasus L.) : I. Effect on Xylem Function and Shoot Water Status.乙烯利诱导樱桃(Prunus cerasus L.)流胶病:I. 对木质部功能和新梢水分状况的影响。
Plant Physiol. 1982 Aug;70(2):547-55. doi: 10.1104/pp.70.2.547.
10
Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.替代庞贝病中的酸性α-葡萄糖苷酶:重组酶和转基因酶效力相当,但均不能完全清除II型肌纤维中的糖原。
Mol Ther. 2005 Jan;11(1):48-56. doi: 10.1016/j.ymthe.2004.09.017.